Bohus BioTech

What Bohus BioTech does

Bohus BioTech AB is a Swedish hyaluronic acid (HA) specialist that develops, manufactures, and distributes HA-based medical products across three therapeutic areas: aesthetics (Decoria PURE dermal fillers), ophthalmics (Minivisc Plus OVD for cataract surgery), and orthopedics (Lubravisc Bio intra-articular injection for knee osteoarthritis). The company's technical foundation is SHAPE (Smart Hyaluronic Acid PurE) Technology, a proprietary gel-manufacturing process that preserves the natural entangled form of HA molecules and requires only ~1% BDDE cross-linking modification versus 8%+ for many competitors, combined with a proprietary purification process that the company states achieves market-unrivalled purity for some products. All products are bio-fermented and non-animal in origin, manufactured in-house at a 6,000m2 ISO 14644-compliant facility in Strömstad, Sweden, with cleanrooms meeting ISO Class 5-7 standards.

The company operates a multi-channel go-to-market model targeting medical professionals (aesthetic injectors, ophthalmic surgeons, orthopedic specialists) and hospitals. Distribution is primarily through a network of local distributors across 60+ markets worldwide, supplemented by direct B2B sales contact, a small e-commerce storefront (decoriapure.com) for Decoria starter kits, and a dedicated OEM/CDMO plus private-label service line that allows partners to launch their own branded HA products. Revenue is generated from product sales (dermal fillers, OVDs, orthopedic injectables), CDMO contract services, and private-label licensing arrangements. Pricing is quote-based and not publicly disclosed; the company positions itself on premium quality at competitive value enabled by streamlined in-house operations.

The company has been bootstrapped/self-funded for approximately 30 years with no disclosed funding rounds, no parent company, and no public listing. The executive team includes CEO Erik Diedrich, CSO Matilda Mitchell, COO Jonas Hultén, and Head of Quality & Regulatory Affairs Mojgan Sahba, with a broader operational team spanning R&D, regulatory affairs, QC, production, and cleanroom operations. Recent strategic activity has centered on the 2025 Decoria PURE rebrand, the upcoming launch of Decoria Pure Jawline, and continued expansion of OEM/CDMO and private-label offerings.

Name

Bohus BioTech

Legal name

Bohus BioTech AB

Website

https://bohusbiotech.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

Bohus BioTech AB is a Swedish hyaluronic acid specialist that develops, manufactures, and distributes HA-based medical products across aesthetics (Decoria fillers), ophthalmics (Minivisc OVD), and orthopedics (Lubravisc) to physicians, clinics, and hospitals in 60+ markets.

Ownership category

akta.pro rank

Headquarters

HQ city

Strömstad

HQ country

Sweden

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Aesthetics - Decoria Dermal Fillers: Sales of premium hyaluronic acid dermal fillers under the Decoria brand, including Pure Lips, Pure Volume, Pure Cheeks, and Pure Jawline (upcoming). Distributed to aesthetic practitioners, clinics, and physicians globally.
2. Ophthalmics - Minivisc Plus OVD: Sales of ophthalmic viscosurgical devices (OVDs) for cataract surgery and other eye procedures. High molecular weight HA-based products sold to ophthalmic surgeons and hospitals.
3. Orthopaedics - Lubravisc Bio: Sales of biocompatible viscoelastic HA injectable for treatment of mild to moderate osteoarthritis of the knee joint. Distributed to orthopedic specialists and hospitals.
4. Private Label Solutions: Distribution of products under partner brands through private label arrangements, giving partners control over quality, pricing, and branding.
5. OEM/CDMO Services: Contract manufacturing and development services for customized hyaluronic acid-based products, from formulation development to full-scale production, for partners seeking to bring their own products to market.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Bohus BioTech researches, develops, manufactures, and distributes premium hyaluronic acid (HA)-based medical products across three therapeutic disciplines: aesthetics (Decoria® PURE dermal fillers — Pure Lips, Pure Volume, Pure Cheeks, Pure Jawline), ophthalmics (Minivisc® Plus OVD for cataract surgery), and orthopaedics (Lubravisc® Bio for knee osteoarthritis). All products are built on bio-fermented, non-animal HA and the proprietary SHAPE™ Technology platform. The company additionally offers OEM/CDMO contract manufacturing and private label solutions for partners commercializing their own HA brands.

Product overview

Bohus BioTech is a Swedish hyaluronic acid company with 30 years of experience developing and manufacturing premium HA-based medical products across three disciplines: aesthetics (Decoria® PURE dermal fillers), ophthalmics (Minivisc® Plus OVD), and orthopaedics (Lubravisc® Bio). The product portfolio centers on the proprietary SHAPE™ Technology platform that enables production of high-purity HA products with only 1% modification. Key products include four Decoria® PURE dermal fillers (Lips, Volume, Cheeks, Jawline) for aesthetic applications, Minivisc® Plus for cataract surgery, and Lubravisc® Bio for knee osteoarthritis treatment. All products are manufactured in-house at the company's 6,000m² facility in Strömstad, Sweden and distributed to 60+ markets worldwide. The company also offers OEM/CDMO and private label services.

Differentiator

Problem solved

Functional benefit

Brands

• Decoria®: Premium hyaluronic acid dermal fillers collection featuring SHAPE™ Technology with only 1% modification. Includes PURE Lips, PURE Volume, PURE Cheeks, and PURE Jawline (coming soon) for various aesthetic applications.
• Minivisc® Plus
• Lubravisc® Bio
• SHAPE™ Technology

Products and services

• Decoria® Pure Lips

Quantifiable outcome

• Clinical study showed Decoria Pure Cheeks maintained statistically significant cheekbone improvement (0.78 median, p=.003) at 300 days post-treatment in 90-patient study
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves1 record

Expansion highlights4 records

Direct peers

• Bioventus: Markets Durolane and Supartz HA viscosupplements for joint pain, competing with Bohus's Lubravisc Bio franchise; serves the same orthopedic specialists and rheumatologists globally.
• Merz Aesthetics: Markets Belotero Balance and other HA-based aesthetic injectables sold through the same physician channels as Decoria; comparable specialty dermatology aesthetics competitor with overlapping global distribution.
• Galderma: Global specialty company whose Restylane/Emervel HA dermal filler portfolio directly competes with Bohus's Decoria line; both target the same aesthetic injectors with HA-based volumizers and share a premium positioning.
• Anika Therapeutics: Sells Monovisc and Orthovisc HA intra-articular injections for knee osteoarthritis, directly competing with Lubravisc Bio; both monetize high-purity HA technology in the orthopaedic viscosupplementation segment.
• Sinclair Pharma: Sells MaiLi and Perfectha HA dermal fillers into the same aesthetic injector channel as Decoria; comparable European-based specialty aesthetics company with multi-region distribution.
• Teoxane: Swiss-based developer of the RHA (Resilient Hyaluronic Acid) dermal filler range; competes head-to-head with Decoria in facial aesthetics with comparable premium, low-modification HA positioning.
• Croma-Pharma: Austrian manufacturer with a HA-based aesthetics portfolio (saypha) and viscosurgical/orthopaedic HA franchises; the closest multi-discipline HA peer to Bohus across aesthetics, ophthalmics, and orthopaedics.

Broad incumbents

• Alcon: Global ophthalmic surgical leader whose OVDs and surgical device portfolio competes with Minivisc Plus in cataract and intraocular surgery, serving the same ophthalmic surgeon customers as Bohus.
• Allergan Aesthetics (AbbVie): Owner of the Juvederm HA filler franchise and broader aesthetics portfolio (Botox, CoolSculpting); competes with Decoria across the same customer base while benefiting from a much larger commercial and R&D footprint.
• Bausch + Lomb: Large ophthalmic company whose surgical portfolio includes ophthalmic viscosurgical devices (OVDs) competing with Minivisc Plus; broader scope but directly overlaps in cataract surgery viscoelastic supply.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bohus-biotech

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bohus BioTech